Similarly, a set of 11 potential therapeutic targets (AKT1, CCND1, CASP3, CTNNB1, EGF, EGFR, MYC, MAPK3, STAT3, TNF, TP53) was directly related to the KEGG pathway “hepatitis C” and interconnected with 23 compounds (SQ7, ZJ11, ZJ3, ZJ4, CBM9, CF2, CF3, QYS8, ZJ8, CL3, CL5, ZJ6, DSL4, DSL5, JTS1, TM12, XYS18, CL2, ZJ10, ZJ12, ZJ2, DSL6, ZZS1; Table S2). This evidence concerns the gene TP53 and hepatitis C virus infection.